Merit Medical Systems, Inc. logo MMSI - Merit Medical Systems, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 11
HOLD 2
SELL 1
STRONG
SELL
0
| PRICE TARGET: $95.00 DETAILS
HIGH: $107.00
LOW: $78.00
MEDIAN: $97.50
CONSENSUS: $95.00
UPSIDE: 48.04%

Stock News

Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)

Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)

Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026.

May 01, 2026 10:21 PM seekingalpha.com
Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance

Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance

Financial Highlights† Reported revenue of $381.9 million, up 7% Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* increased 4%, excluding revenue from divested product line GAAP operating margin of 11.6%, compared to 11.5% in prior year period Non-GAAP operating margin* of 19.7%, compared to 19.3% in prior year period GAAP EPS $0.68, up 39% Non-GAAP EPS* $0.94, up 9% Free cash flow* generation of $24.7 million, up 26% Business Developments On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25.5 million was paid in cash at closing On April 1, 2026, Merit acquired View Point Medical, Inc., manufacturer of the OneMark® Detection Imaging System and OneMark Tissue Markers, for $140 million, of which $90 million was paid in cash at closing Beginning in the first quarter of 2026, Merit reorganized the presentation of revenue into two product categories – Foundational and Therapeutic - to better reflect the clinical uses of our diverse portfolio of products** † Comparisons above are calculated for the current quarter compared with the first quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.

Apr 30, 2026 12:05 PM globenewswire.com

Price Targets